Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7381 to 7395 of 7675 results

  1. Falls: the assessment and prevention of falls in older people (CG21)

    This guideline has been updated and replaced by NICE guideline CG161.

    Clinical guideline
    Published
    24 November 2004

  2. Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care (CG22)

    This guideline has been updated and replaced by NICE guideline CG113.

    Clinical guideline
    Published
    6 December 2004

  3. Depression: management of depression in primary and secondary care (CG23)

    This guidance has been updated and replaced by NICE guideline CG90.

    Clinical guideline
    Published
    6 December 2004

  4. Lung cancer: diagnosis and treatment (CG24)

    This guideline has been updated and replaced by NICE guideline CG121.

    Clinical guideline
    Published
    23 February 2005

  5. Violence: short-term management for over 16s in psychiatic and emergency departments (CG25)

    This guideline has been updated and replaced by NICE guideline NG10.

    Clinical guideline
    Published
    23 February 2005

  6. Post-traumatic stress disorder: management (CG26)

    This guidance has been updated and replaced by NICE guideline NG116.

    Clinical guideline
    Published
    23 March 2005

  7. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development [GID-TA11443] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Technology appraisal guidance
    Published
    12 May 2021

  11. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  13. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Technology appraisal guidance
    Published
    12 June 2024